Sapan Desai has inactivated his license in Illinois, where multiple malpractice lawsuits against him are pending, and obtained a new one in Ohio.

The changes, which affect the declarations authors have to sign and the peer-review process, have received a mixed response from the scientific community.

Pier Paolo Pandolfi left Harvard University last year following allegations of sexual harassment, and has since been accused of research misconduct.

Fast science—with all its warts—is making unprecedented progress in the fight against COVID-19.

The company behind a now-discredited study on hydroxychloroquine also posted a report that has been cited by Latin American governments recommending ivermectin as a possible coronavirus treatment. Clinicians there say the effects have been extremely damaging.

Our handbook on best practices for quality assurance in biomedicine can help funding agencies shore up research integrity—which is especially needed at a time when mistakes can have outsize effects.

The company had helped develop a tool to aid decision-making in distributing limited medical equipment among coronavirus patients, but two high-profile retractions call into question the validity of Surgisphere’s work in toto.

All authors other than company founder and CEO Sapan Desai were “unable to complete an independent audit of the data,” The Lancet states.

NEJM and The Lancet issue expressions of concern as researchers question where the company got its data on thousands of coronavirus patients.